Trials / Completed
CompletedNCT02095509
Pharmacokinetics of Enoxaparin in Intensive Care Patients
Plasma Anti-FXa Concentration After Continuous Intravenous Infusion and Subcutaneous Dosing of Enoxaparin for Thromboprophylaxis in Critically Ill Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Tampere University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the pharmacokinetics of the thromboprophylactic agent enoxaparin in critically ill patients by comparing plasma anti-factor Xa activity when enoxaparin is administered either as a continuous intravenous infusion or subcutaneous bolus once daily. To investigate possible ongoing coagulation by coagulation markers during antithrombotic therapy with standard doses of enoxaparin
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enoxaparin | Drug class: Low-molecular weight heparin |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2016-06-30
- Completion
- 2016-09-30
- First posted
- 2014-03-24
- Last updated
- 2017-10-27
Locations
2 sites across 1 country: Finland
Source: ClinicalTrials.gov record NCT02095509. Inclusion in this directory is not an endorsement.